Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
This protocol is to provide follow-up medical/surgical visits for DCS patients who are long term survivors and may not currently be a participant entered on an active research protocol. No investigational treatments or standard treatments will be administered on this protocol.
NCT00001503 — Breast Cancer
Status: Completed
http://inclinicaltrials.com/breast-cancer/NCT00001503/
Continuing Treatment for Children and Adults in the Center for Cancer Research
This protocol is to provide continuing medical/surgical/radio-therapeutic care, treatment and follow-up for NCI patients not currently entered on an active research protocol. No investigational treatments will be administered on this protocol.
NCT00001295 — Cancer
Status: Completed
http://inclinicaltrials.com/cancer/NCT00001295/
A Clinical Validation Study to Demonstrate the Effectiveness of an Artificial Intelligence Algorithm (DERM) to Identify Skin Cancer in Patients Undergoing a Skin Biopsy
This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the US and European population.
NCT05126173 — Squamous Cell Carcinoma
Status: Completed
http://inclinicaltrials.com/squamous-cell-carcinoma/NCT05126173/
Identification of a Genomic/Transcriptomic Signature for Ageing and Predisposition to Skin Cancer in Normal Sun-exposed Skin
The aim of this study is to identify genetic patterns in normal ageing skin in order to better understand age-related changes. Data has suggested that skin ageing has a genetic basis and past studies have identified genes that promote skin aging due to sun exposure.
NCT03265678 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT03265678/
Cancer Sensing: Evaluation of Odour Sampling Techniques to Support the Non-invasive Early Detection of Skin Cancer - Proof of Concept
To evaluate the suitability of two odour capturing techniques for early detection of skin cancer.
NCT04206995 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT04206995/
Phase II Investigation of the Histopathologic Effect of Calcium Electroporation on Cancer in the Skin (CAEP-B)
In this phase II study we investigate the effect of calcium electroporation on cancer in the skin investigated by histopathology.
NCT04259658 — Cancer
Status: Completed
http://inclinicaltrials.com/cancer/NCT04259658/
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.
NCT04088318 — Hand-Foot Skin Reaction (HFSR)
Status: Active, not recruiting
http://inclinicaltrials.com/hand-foot-skin-reaction-hfsr/NCT04088318/
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
NCT03944941 — Skin Squamous Cell Carcinoma
Status: Active, not recruiting
http://inclinicaltrials.com/skin-squamous-cell-carcinoma/NCT03944941/
Ambulatory Process of Elderly Patient for Skin and Breast Cancer Surgery
The number of surgical procedures performed in ambulatory hospitalization for cancers of the skin or breast is increasing for medical and economic reasons. But the protocols of care and the clinical pathways are poorly adapted for elderly patients with physical or cognitive impairment. The goal of this study is to test the impact of an oncology ambulatory surgical care in patients aged 75 years or older, with breast or skin cancer and treated in Henri Mondor hospital on the increase in the proportion of patients operated on an outpatient basis
NCT03604666 — Breast Cancer
Status: Recruiting
http://inclinicaltrials.com/breast-cancer/NCT03604666/
Efficacy and Safety of Single Agent Pan-HER Inhibitor Dacomitinib in the Treatment of Locally Advanced Unresectable or Metastatic Squamous Cell Cancer of the Skin or With Clinical Contraindication to Surgery
This is an open label, monocentric, uncontrolled phase II trial with Dacomitinib, a pan-HER inhibitor, in unresectable or metastatic skin SCC. HER2 expression is common in skin SCC, being reported with high rates, even if in small studies. Coexpression of EGFR, HER2 and HER3 is present in skin SCCs but not in normal skin and it could be associated with the malignant phenotype. In this frame Dacomitinib could play a role in the increase of the response rate.
NCT02268747 — Skin Squamous Cell Cancer
Status: Active, not recruiting
http://inclinicaltrials.com/skin-squamous-cell-cancer/NCT02268747/